Trial Profile

Hepatic Artery Infusion Chemotherapy(HAIC) Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
Indications Liver cancer
Focus Therapeutic Use

Most Recent Events

24 Oct 2023 Results (as of 18 April 2023, n=72) assessing efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anlotinib and TQB2450 (PD-L1 monoclonal antibody) as adjuvant therapy for pts with HCC at high risk of recurrence after hepatectomy, presented at the 48th European Society for Medical Oncology Congress.
08 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com